Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

✨ Onyx Summary Alzheon, Inc. announced a peer-reviewed publication in CNS Drugs synthesizing evidence that hippocampal volume on MRI tracks cognitive decline and therapeutic response in early symptomatic Alzheimer’s disease, supporting its use as a surrogate marker in clinical development. The review proposes a hippocampal volume preservation threshold (≥40 mm³

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

✨ Onyx Summary Belite Bio commenced an underwritten public offering of ADSs, with all shares sold by the company and an additional 30-day underwriter option for extra ADSs, subject to market conditions. Proceeds are earmarked for commercialization buildout, pipeline development and expansion, and general corporate purposes, with Morgan Stanley, Leerink, BofA

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

✨ Onyx Summary Belite Bio reported positive topline Phase 3 DRAGON results showing its oral therapy tinlarebant met the primary endpoint in Stargardt disease type 1, delivering a statistically significant 35.7% reduction in retinal lesion growth versus placebo over 24 months in 104 adolescent patients. The company said the safety

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

✨ Onyx Summary Recursion announced it will host a December 8, 2025 company webinar to present an updated clinical readout from the ongoing TUPELO Phase 1b/2 trial evaluating REC-4881 monotherapy in patients with familial adenomatous polyposis, including new safety and efficacy data. Salt Lake City, Dec. 01, 2025 – Recursion (Nasdaq:

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

✨ Onyx Summary Cellares appointed Ali Soleymannezhad as Chief Commercial Officer to lead global commercial strategy as it scales its IDMO Smart Factory network across the U.S., Europe, and Japan, positioning the company for commercial expansion ahead of a potential IPO. The hire underscores Cellares’ strategy to address global cell

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

✨ Onyx Summary Seer, Inc. announced publication in Nature Genetics of a large-scale GWAS demonstrating that its Proteograph platform’s peptide-level mass spectrometry is critical for accurately validating protein–gene associations and reducing false signals common in affinity-based proteomics. The study, spanning ~1,600 multi-ethnic samples, shows that up to one-third

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

✨ Onyx Summary Rocket Pharmaceuticals announced that CEO Dr. Gaurav Shah will participate in a fireside chat and investor meetings at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance provides a platform to engage investors on Rocket’s late-stage gene therapy pipeline and strategic priorities as it

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

✨ Onyx Summary Lexicon Pharmaceuticals announced that company management will participate in fireside chats at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the Evercore 8th Annual Healthcare Conference on December 4, 2025, with live and replay access available through the company’s investor website. THE WOODLANDS,

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

✨ Onyx Summary enGene Holdings Inc. announced that Chief Strategy and Operations Officer Alex Nichols, Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a webcast available via the company’s investor website. BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

✨ Onyx Summary Foghorn Therapeutics announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025, with a webcast available via the company’s investor website. CAMBRIDGE, Mass., Nov. 25, 2025 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a

Keros Therapeutics Announces Final Results of Tender Offer

Keros Therapeutics Announces Final Results of Tender Offer

✨ Onyx Summary Keros Therapeutics, Inc. announced the final results of its cash tender offer, repurchasing 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender, which applied a final proration factor of roughly 62.3%, concludes

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics to Participate in Upcoming December Conferences

✨ Onyx Summary Perspective Therapeutics announced that members of its senior leadership team will participate in fireside chats and investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. SEATTLE, Nov. 20, 2025 – November 20, 2025